Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis.

By Ivan V. Gregoretti, Yun-Mi Lee, H. Goodson. Journal of Molecular Biology, 2004

1,444 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/a2c38a4e704ce70e16145583dcc81a760c697ae2

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

Citations in the corpus

HDAC family: What are the cancer relevant targets? (2009, background): “HDACs are grouped into class I, class II, class III and class IV based on their sequence homology to their yeast orthologues Rpd3, HdaI and Sir2, respectively [5,6].”
Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents (2015, background): “Class I family of HDACs consists of HDAC1, 2, 3 and 8 proteins sharing sequence homology with yeast reduced potassium dependency-3 (Rpd3), and are mainly located in the nucleus of the cells [6,7].”
Histone Deacetylase Inhibitors: Overview and Perspectives (2007, background): “HDACs are known as HDACs because histones were considered the most important target of HDACs (3, 4).”
β-Hydroxybutyrate (2017, neutral): “BHB inhibits class I histone deacetylases (HDACs) (41), a family of proteins that have important roles in regulating gene expression by deacetylating lysine residues on histone and nonhistone proteins (reviewed in References 85, 90, and 151).”
Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets (2015, background): “2007), while class III HDACs (also known as sirtuins) are an unrelated class of NAD-dependent deacetylases (Gregoretti et al. 2004; Landry et al. 2000).”
HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention (2007, neutral): “In humans, members of the classical family include HDAC1, -2, -3 and -8 (class I); HDAC4, -5, -6, -7, -9 and -10 (class II); and HDAC11 (class IV) (reviewed by Cress and Seto, 2000; Grozinger and Schreiber, 2002; Blander and Guarente, 2004; Gregoretti et al., 2004).”
Sirt1 and the Mitochondria (2016, background): “HDAC11 has only fairly low homology to both RPD3 and HDA1, and has been proposed to constitute a separate class IV (Gregoretti et al., 2004) so as to be distinguishable from the class III HDACs, or sirtuins.”
The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men (2008, background): “HDACs can also be grouped according to phylogenetic analysis and sequence homolog”
Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes (2011, background): “Based on sequence phylogeny and function, there are four distinct classes of HDAC: class I (HDAC1, 2, 3 and 8), class IIa (HDAC4, 5, 7 and 9), class IIb (HDAC6 and 10) and class IV (HDAC11) represent Zn 2+ -dependent amidohydrolases, whereas class III comprises the mechanistically diverse NAD + -dep”
Histone deacetylase inhibitors: molecular mechanisms of action (2007, background): “Oncogene inhibitory effect against HDAC6 and HDAC8 (Hu et al., 2003).”
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer (2006, background): “An extensive phylogenetic analysis of HDACs has been performe”
Therapeutic application of histone deacetylase inhibitors for central nervous system disorders (2008, background): “In fact, phylogenetic analysis of bacterial HDAC relatives suggests that evolutionary development of modern HDACs preceded the evolution of histone proteins, and raises the possibility that the primary activity of some HDACs is directed against non-histone substrate”
Genetics and genomics of pulmonary arterial hypertension. (2013, background): “The 18 mammalian HDACs are grouped into 4 classes (101).”